Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

Boundless Bio, Inc. Completes Merger with Serapha Bio, Inc.

PUBLIC · BOLDAug 28, 2026about 2 hours ago

Acquiring Company

Boundless Bio

Acquired Company

Serapha Bio

La JollaHat YaiBiotechnologyBiotechnologyHealth CareTherapeutics

Description

On June 22, 2026, Boundless Bio, Inc. entered into a merger agreement with Serapha Bio, Inc. Under the terms of the agreement, Merger Sub will merge into Serapha, with Serapha becoming a wholly owned subsidiary of Boundless Bio. An amendment to the merger agreement was executed on August 28, 2026 to finalize details of the transaction.

Company Information

Company

Boundless Bio

Location

11099 N Torrey Pines Road

La Jolla, California, United States

About

Boundless Bio is discovering and developing novel cancer therapeutics based on the role of extrachromosomal DNA (ecDNA) in driving tumorigenesis, resistance and recurrence. When DNA in cancer cells comes off chromosomes, “extrachromosomal DNA (ecDNA),” it becomes unbound and unwound, thereby enabling numerous copies of cancer-causing genes, driving cancer cells to grow and allowing them to resist treatment. At Boundless Bio, we are counterattacking this ecDNA phenomenon with boundless innovation and boundless energy to develop powerful new cancer medicines that eliminate cancer cells’ ability to employ ecDNA to survive. Our Culture: At Boundless, you’ll experience what it means to be out in front of the wave. Our unprecedented science takes us to new shores, and our team navigates the best breaks. We’re leaders in our field, and we’re dedicated to the cause of understanding and treating intractable cancers. Every employee at Boundless makes an unbridled impact on our capabilities and our culture. We’ll help you expand your abilities and defy your bounds by providing meaningful work and unbounded opportunities. Career development is essential at Boundless. We’re all in on this fight against cancer– collaboration is requisite to our success. We have a team of people who ask, offer, and accept help without regard for ego. We know that receiving support is energizing, and giving help is fulfilling. We are inspired by the patients who are reliant upon our success. At Boundless, we’re all in. We are unbound by convention, bound to save lives.

Don't miss Boundless Bio's next move

Get an email the moment Boundless Bio makes an acquisition, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Related People

Jami
Likely contact at this company
••••••••@••••••••

See Jami's verified email →

Predictive Intelligence
Strategic

ML-powered predictions for Boundless Bio's next move

Learn about Strategic plan

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed

Frequently asked

Who acquired Serapha Bio?

Serapha Bio was acquired by Boundless Bio, based in La Jolla. The deal was reported on August 28, 2026. Boundless Bio is discovering and developing novel cancer therapeutics based on the role of extrachromosomal DNA (ecDNA) in driving tumorigenesis, resistance and recurrence. Boundless Bio is publicly traded (BOLD) and operates in Biotechnology.

When did Boundless Bio acquire Serapha Bio?

Boundless Bio's acquisition of Serapha Bio was reported on August 28, 2026. On June 22, 2026, Boundless Bio, Inc. entered into a merger agreement with Serapha Bio, Inc. Under the terms of the agreement, Merger Sub will merge into Serapha, with Serapha becoming a wholly owned subsidiary of Boundless Bio. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Serapha Bio do?

Serapha Bio is a privately held company focused on developing treatments for genetic diseases. The company is geared towards bringing innovative therapies to market for conditions such as Alpha-1 Antitrypsin Deficiency. It is privately held, operating in Biotechnology, and is based in Hat Yai.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.